Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors

Cancer Letters

Volumn 131, Issue 1, 1998, Pages 35-44

  St Croix, Brad ^a   Man, Shan ^a   Kerbel, R S ^a,b  

^a Biological Sciences   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Drug resistance; Hyaluronidase treatment; Solid tumors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; HYALURONIDASE; PACLITAXEL; VALSPODAR;

CONFERENCE PAPER; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; CELL ADHESION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HYALURONOGLUCOSAMINIDASE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; P-GLYCOPROTEIN; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

BOVINAE;

EID: 0032508627     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00199-2     Document Type: Conference Paper

References (48)

1. Allen H.J., Porter C., Gamarra M., Piver M.S., Johnson E.A. Isolation and morphologic characterization of human ovarian carcinoma cell clusters present in effusions. Exp. Cell Biol. 55:1987;194-208.
2. Barnard N.J., Hall P.A., Lemoine N.R., Kadar N. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J. Pathol. 152:1987;287-295.
3. Baumgartner G., Fortelny A., Zanker K.S., Kroczek R. Phase I study in chemoresistant loco-regional malignant disease with hyaluronidase. Reg. Cancer Treat. 1:1988;55-58.
4. Bjorge L., Junnikkala S., Kristoffersen E.K., Hakulinen J., Matre R., Meri S. Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis. Br. J. Cancer. 75:1997;1247-1255.
5. Boehm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
6. Briffod M., Spyratos F., Hacene K., Tubiana-Hulin M., Pallud C., Gilles F., Rouesse J. Evaluation of breast carcinoma chemosensitivity by flow cytometric DNA analysis and computer assisted image analysis. Cytometry. 13:1992;250-258.
7. KIP1. J. Clin. Invest. 97:1996;1983-1988.
8. Chignola R., Foroni R., Franceschi A., Pasti M., Candiani C., Anselmi C., Fracasso G., Tridente G., Colombatti M. Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin. Br. J. Cancer. 72:1995;607-614.
9. DeWys W.D. A quantitative model for the study of the growth and treatment of a tumor and its metastases with correlation between proliferative state and sensitivity to cyclophosphamide. Cancer Res. 32:1972;367-373.
10. Drewinko B., Patchen M., Yang L.-Y., Barlogie B. Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res. 41:1981;2328-2333.
11. Eijgenraam F. Things start getting sticky for a cell surface enzyme. Science. 261:1993;833.
12. Gerdes J., Lelle R.J., Pickartz H., Heidenreich W., Schwarting R., Kurtsiefer L., Stauch G., Stein H. Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J. Clin. Pathol. 39:1986;977-980.
13. Gorlach A., Herter P., Hentschel H., Frosch P.J., Acker H. Effects of nIFN β and rIFN gamma on growth and morphology of two human melanoma cell lines: comparison between two- and three-dimensional culture. Int. J. Cancer. 56:1994;249-254.
14. Graham C.H., Kobayashi H., Stankiewicz K.S., Man S., Kapitain S.J., Kerbel R.S. Rapid acquisition of multicellular drug resistance after a single transient exposure of mammary tumor cells to alkylating agents. J. Natl. Cancer Inst. 86:1994;975-982.
15. Harper J.W., Elledge S.J. Cdk inhibitors in development and cancer. Curr. Opin. Gen. Dev. 6:1996;56-64.
16. Houghton P.J., Kaye S.B. Multidrug resistance is not an important factor in therapeutic outcome in human malignancies. J. Natl. Inst. Health Res. 6:1994;55.
17. Kerbel R.S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays. 13:1991;31-36.
18. Kerbel R.S. A cancer therapy resistant to resistance. Nature. 390:1997;335-336.
19. Kerbel R.S., Rak J., Kobayashi H., Man M.S., St. Croix B., Graham C.H. Multicellular resistance: a new paradigm to explain aspects of acquired drug resistance of solid tumors. Cold Spring Harbor Symp. Quant. Biol. Mol. Genet. Cancer. 59:1994;661-672.
20. Kerbel R.S., St. Croix B., Rak J., Graham C. Is there a role for 'anti-adhesives' as chemosensitizers in the treatment of solid tumors by chemotherapy? Bull. Inst. Pasteur. 92:1995;248-256.
21. Kobayashi H., Man S., Kapitain S.J., Teicher B.A., Kerbel R.S. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc. Natl. Acad. Sci. USA. 90:1993;3294-3298.
22. Kohno N., Ohnuma T., Truog P. Effects of hyaluronidase on doxorubicin penetration into squamous carcinoma multicellular tumor spheroids and its cell lethality. J. Cancer Res. Clin. Oncol. 120:1994;293-297.
23. O'Reilly S.M., Camplejohn R.S., Rubens R.D., Richards M.A. DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur. J. Cancer. 213:1992;681-683.
24. Ochalek T., von Kleist S. Study of the resistance of tumor-cell spheroids to penetration and lysis by activated effector cells. Int. J. Cancer. 57:1994;399-405.
25. Oda T., Kanai Y., Oyama T., Yoshiura K., Shimoyama Y., Birchmeier W., Sugimura T., Hirohashi S. E-Cadherin gene mutations in human gastric carcinoma cell lines. Proc. Natl. Acad. Sci. USA. 91:1994;1858-1862.
26. Olive P.L., Durand R.E. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev. 13:1994;121-138.
27. Peluso J.J., Pappalardo A., Trolice M.P. N-Cadherin-mediated cell contact inhibits granulosa cell apoptosis in a progesterone-independent manner. Endocrinology. 137:1996;1196-1203.
28. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8:1994;9-22.
29. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 78:1994;59-66.
30. Remvikos Y., Beuzeboc P., Zajdela Z., Voillemot N., Magdelenat H., Pouillart P. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J. Natl. Cancer Inst. 81:1989;1383-1387.
31. Remvikos Y., Jouve M., Beuzeboc P., Viehl P., Magdelenat H., Pouillart P. Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur. J. Cancer. 29A:1993;1843-1848.
32. Remvikos Y., Mosseri V., Zajdela A., Fourquet A., Durand J.C., Pouillart P., Magdelenat H. Prognostic value of the S-phase fraction of breast cancers treated by primary radiotherapy or neoadjuvant chemotherapy. Ann. N. Y. Acad. Sci. 32:1993;193-203.
33. Sakata K., Kwok T.T., Gordon G.R., Waleh N.S., Sutherland R.M. Resistance to verapamil sensitization of multidrug resistant cells grown as multicellular spheroids. Int. J. Cancer. 59:1994;282-286.
34. Slingerland J.M., Hengst L., Pan C.-H., Alexander D., Stampfer M.R., Reed S.I. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol. Cell. Biol. 14:1994;3683-3694.
35. Spruß T., Bernhardt G., Schonenberger H., Schiess W. Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma. Cancer Res. Clin. Oncol. 121:1995;193-202.
36. Spyratos F., Briffod M., Tubiana-Hulin M., Andrieu C., Mayras C., Pallud C., Lastry S., Rouesse J. Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. Cancer. 69:1992;470-475.
37. Kip1 on adhesion-dependent resistance of tumor cells to anticancer agents. Nat. Med. 2:1996;1204-1210.
38. St. Croix B., Kerbel R.S. Cell adhesion and drug resistance in cancer. Curr. Opin. Oncol. 9:1997;549-556.
39. St. Croix B., Rak J.W., Kapitain S., Sheehan C., Graham C.H., Kerbel R.S. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J. Natl. Cancer Inst. 88:1996;1285-1296.
40. Sulkes A., Livingston R.B., Murphy W.K. Tritiated thymidine labeling index and response in human breast cancer. J. Natl. Cancer Inst. 62:1979;513-515.
41. Sutherland R.M. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science. 240:1988;177-184.
42. Teicher B.A., Herman T.S., Holden S.A., Wang Y., Pfeffer M.R., Crawford J.W., Frei III E. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science. 247:1990;1457-1461.
43. Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 78:1994;67-74.
44. Twentyman P.R., Reeve J.G., Koch G., Wright K.A. Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin). Br. J. Cancer. 62:1990;89-95.
45. Valeriote F., van Putten L. Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res. 35:1975;2619-2630.
46. West G.W., Weichselbaum R., Little J.B. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res. 40:1980;3665-3668.
47. Yang Z.-Y., Perkins N.D., Ohno T., Nabel E.G., Nabel G.J. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat. Med. 1:1995;1052-1056.
48. Zhang Z., Vuori K., Reed J.C., Ruoslahti E. The α5β1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc. Natl. Acad. Sci. USA. 92:1995;6161-6165.